Bicycle Therapeutics (NASDAQ:BCYC) Receives New Coverage from Analysts at Cantor Fitzgerald
Cantor Fitzgerald began coverage on shares of Bicycle Therapeutics (NASDAQ:BCYC) in a research note released on Monday morning, Benzinga reports.…
Bicycle Therapeutics Limited (NASDAQ:BCYC) Sees Large Growth in Short Interest
Bicycle Therapeutics Limited (NASDAQ:BCYC) was the target of a significant growth in short interest in September. As of September 15th,…
Analysts Set Bicycle Therapeutics Limited (NASDAQ:BCYC) Price Target at $21.30
Shares of Bicycle Therapeutics Limited (NASDAQ:BCYC) have earned a consensus rating of “Buy” from the eight research firms that are…
Bicycle Therapeutics Announces Pipeline Progress Update
CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics…